Dynacure Receives Rare Pediatric Disease…
Strasbourg (France) / Philadelphia (USA)July 30, 2020Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 (DNM2), for the treatment of Myotubular and Centronuclear Myop
READ MOREDynacure Announces Presentations at Upcoming…
Strasbourg (France) / Philadelphia (USA)July 28, 2020Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today that the company is presenting at several virtual investor conferences during August 2020. LifeSci Partners: Private Summer Symposium Dynacure's CFO, David Garrett, will present a company overview at 8am-8:45am ET on August 5, 2020 William Blai
READ MOREDynacure Announces Presentation at Jefferies…
Strasbourg (France) / Philadelphia (USA)May 27, 2020Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today that Stephane van Rooijen (M.D. MBA), Chief Executive Officer of Dynacure, will present a company overview at the Jefferies Virtual Global Healthcare Conference on June 3 rd , 2020 at 8:00 am ET. About Dynacure Dynacure is a clinical-stage drug develo
READ MOREDynacure Announces €50M ($55M) Series…
Strasbourg (France) / Philadelphia (USA)April 2, 2020Funding supports ongoing Phase 1 /2 ‘Unite-CNM’ study of DYN101 in Patients with Myotubular and Centronuclear Myopathies Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today the close of a €50 million Series C financing led by Perceptive Advisors. New investors participating in this financing includ
READ MOREDynacure Announces First Patient Dosed…
Strasbourg (France)March 5, 2020Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that the first patient has been dosed with DYN101 in a Phase 1 / 2 study called 'Unite-CNM'.B This milestone marks the first time any company has dosed a CNM patient with an antisense medicine. DYN101 is an investigational antisense medicine designed to
READ MOREDynacure to Present at 40th…
Strasbourg (France)February 26, 2020Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that the company will be presenting at the 40th Annual Cowen Healthcare Conference being held March 2nd-4th at the Boston Marriott Copley Place hotel. David Garrett (MBA), Chief Financial Officer of Dynacure, will present a company overview on March 2nd,
READ MOREDynacure’s Chief Scientific Officer, Dr.…
Strasbourg (France)November 27, 2019Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that Belinda Cowling, Ph.D., Chief Scientific Officer and co-founder of Dynacure, has received the 2019 Irène Joliot-Curie Prize for Women in Business and Technology. Dr. Cowling was honored for her work in the field of neuromuscular disease research, her
READ MOREDynacure Presents New Preclinical Results…
Strasbourg (France)October 2, 2019Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced two poster presentations at the 24th Annual International Congress of the World Muscle Society (WMS). Dynacure is presenting new preclinical research supporting its lead antisense medicine, DYN101, and data from the prospective Natural History Study of Pa
READ MOREDynacure Wins Ernst & Young’s…
Strasbourg (France)September 18, 2019Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that it has won the 2019 Ernst & Young’s (EY) “Born Global” award for ‘Region Est’, France. The award was received by Stephane van Rooijen (M.D. MBA), Chief Executive Officer of Dynacure, at the 2019 EY Entrepreneur of the Year awards ceremo
READ MOREDynacure to Present at Chardan’s…
Strasbourg (France)September 11, 2019Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that the company will be presenting at the 3rd Annual Chardan Genetic Medicines Conference being held October 7th-October 8th at the Westin Grand Central hotel in New York. Stephane van Rooijen (M.D. MBA), Chief Executive Officer of Dynacure, will presen
READ MOREDynacure Appoints David Garrett as…
Strasbourg (France)September 3, 2019Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced the appointment of David Garrett, MBA, CPA, as Chief Financial Officer. Mr. Garrett will be based in the USA as Dynacure continues to expand their global footprint. Mr. Garrett is an established finance leader with more than 15 years of experience in the
READ MOREDynacure Receives Orphan Drug Designation…
Strasbourg (France)August 8, 2019Company expects to initiate Phase 1 / 2 study ‘Unite-CNM’ in 2H2019 Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2
READ MOREDynacure Receives Orphan Drug Designation…
STRASBOURGJuly 11, 2019Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designation to DYN101 for the treatment of Centronuclear Myopathies (CNM). DYN101, an antisense medicine, is entering a Phase a 1 / 2 study (Unit
READ MOREDynacure Announces Approval of Clinical…
Strasbourg (France)April 30, 2019Company expects to initiate Phase 1 / 2 study ‘Unite-CNM’ in 2H2019 Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Clinical Trial Application (CTA) for DYN101, an investigational antisense medicine designed to modu
READ MOREDynacure receives Research Grant from…
Strasbourg (France)April 25, 2019Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, today announced the award of a research grant of 450 000 euros from Programme d’Investissements d’Avenir (PIA3) Grand Est operated by Bpifrance. The research grant will advance and expand the development of Dynacure’s lead drug program (Dyn-101), an antisense oligonucleotide des
READ MOREDynacure promotes Belinda Cowling (PhD)…
StrasbourgFebruary 12, 2019Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, today announced the promotion of Belinda Cowling (PhD) to Chief Scientific Officer and Leen Thielemans (PhD) to Chief Development Officer. Belinda Cowling’s (PhD) research at the IGBMC (Strasbourg) led to the creation of Dynacure in 2016, of which she is cofounder and was scientific
READ MOREDynacure appoints Georges Gemayel (PhD)…
StrasbourgOctober 9, 2018Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, today announced the appointment of Georges Gemayel (PhD) as chairman of its Board of Directors. "I am very pleased to welcome Georges to Dynacure’s Board of Directors during this exciting stage in our company's growth. His extensive experience will strengthen the team’s mission to
READ MOREInnovative modelling approach by Dynacure/ISMS…
StrasbourgAugust 31, 2018Dynacure’s recent publication in ‘Neuromuscular Disorders’, co-authored with Dr Laurent Servais, Dr Jim Dowling and Dr Valérie Biancalana: ‘An integrated modelling methodology for estimating the prevalence of centronuclear myopathy’ This innovative modelling approach by Dynacure/ISMS resulted in the 1st peer reviewed study on quantification of the CNM patient population with a d
READ MOREDynacure names Chris Freitag (MD)…
Strasbourge (France)July 10, 2018Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today the expansion of its leadership team with the appointment of Chris Freitag (MD) as Chief Medical Officer. He will be responsible for the company’s medical strategy, clinical operations and expand Dynacure’s network with medical and academic organizations. “I’m e
READ MOREDynacure secures €47 million financing…
Strasbourge (France)July 6, 2018Financing will support clinical development of lead antisense oligonucleotide candidate for centronuclear myopathy (CNM), and additional preclinical research programs forotherorphan disorders Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today the completion of a €47 million financing round (~US$55 million) to advance
READ MOREBelinda Cowling (PhD) joins Dynacure…
Strasbourg (France)April 30, 2018Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today that Belinda Cowling (PhD) has joined the management team as Head of Research. Dynacure’s first drug discovery program focuses on centronuclear myopathies (CNM), a rare debilitating disease affecting children and young adults, through the use of an antisense oligonu
READ MOREIonis licenses novel antisense drug…
Carlsbad, Calif. and Strasbourg, FranceNovember 9, 2017Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear myopathy (CNM), for which Ionis earned a $5 million license fee in the form of Dynacure equity. Dynacure will now assume all development and commercialization responsibilities for the pro
READ MOREDynacure joins ongoing Natural History…
Strasbourg (France)September 26, 2017Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathy (CNM), a debilitating rare disease affecting children and young adults. Dynacure’s development program is using an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals. Dynac
READ MOREDynacure appoints its Management Team…
Strasbourg (France)March 9, 2017Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a debilitating rare disease affecting children and young adults. Dynacure’s development program is using an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals. The
READ MOREKurma Partners and Idinvest Partners…
ParisOctober 24, 2016Kurma announced on Monday the 24th of October 2016, that they have entered into a collaboration agreement with Conectus and Ionis Pharmaceutical to launch Dynacure, a Strasbourg-based biotech specializing in the treatment of rare neuromuscular disorders. Dynacure is a spin-off from the IGBMC (Institute of Genetic and Molecular and Cellular Biology – Unistra/INSERM/CNRS) of Strasbourg. “The
READ MORE